Retatrutide Ozempic Trial Doubles Weight Loss for Diabetics

Eli Lilly's experimental drug retatrutide beat Novo Nordisk's Ozempic on both blood sugar and weight loss in a head-to-head retatrutide Ozempic trial, according to results the company reported on Wednesday. The late-stage study, called TRANSCEND-T2D-2, enrolled 1,298 adults with type 2 diabetes whose blood sugar was not controlled well enough on metformin, with or without an additional SGLT2 inhibitor.

What the trial measured

In the retatrutide Ozempic trial, participants received weekly injections of retatrutide at 9 mg or 12 mg, or Ozempic at 2 mg, and researchers tracked them for 80 weeks. Average A1C, a measure of blood sugar over time, fell 2.2 percent in both retatrutide groups, compared with 1.8 percent for Ozempic, from a starting average of 8.3 percent. The difference met the trial's main goal, and the result was statistically significant, Fierce Biotech reported.

Retatrutide works by activating three hormone receptors at once: GLP-1, GIP and glucagon. The combination is meant to suppress appetite, control blood sugar and burn more calories, which is why the drug picked up the nickname triple-G. Ozempic, by contrast, acts on only one of those receptors, and Lilly used its highest approved dose as the comparator.

Weight loss told the sharper story

People on the lower retatrutide dose lost an average of 44.3 pounds, and people on the higher dose lost 47.4 pounds, while people on Ozempic lost 20.9 pounds. In percentage terms, that worked out to roughly a fifth of body weight for retatrutide patients and under a tenth for Ozempic patients. The gap matters because heavier weight loss tends to come with better blood pressure and cholesterol readings, and Lilly said retatrutide also improved non-HDL cholesterol, triglycerides and systolic blood pressure more than Ozempic did.

The study was open-label, meaning participants and researchers knew which drug each person received, a design Lilly chose for a direct comparison rather than a placebo test. The trial is the sixth late-stage study of retatrutide to report strong efficacy, and the first to compare it directly with another incretin medicine, according to pharmaphorum.

Direct comparisons like this one are uncommon in diabetes research, where new drugs are usually tested against a placebo rather than against the best-known rival. That scarcity is part of why the result drew attention well beyond diabetes specialists, since a clear win over Ozempic gives Lilly a stronger case to make to doctors and insurers when it seeks approval.

The trade-offs patients felt

Stronger results came with more stomach trouble. Gastrointestinal events were the most common side effects, with diarrhea, nausea and vomiting reported more often on retatrutide than on Ozempic in Lilly's summary. Treatment discontinuations because of adverse events reached 7.9 percent on the top retatrutide dose, compared with 2.7 percent on Ozempic. Retatrutide is still investigational, which means regulators have not approved it anywhere yet, and Lilly has said it hopes to file for approval early next year.

Why the result lands hard for Novo Nordisk

The retatrutide Ozempic trial result extends Lilly's lead in a market it already dominates with tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management. Analyst forecasts cited in coverage of the results put retatrutide's eventual yearly sales somewhere between ten and twenty-five billion dollars at peak, a range that would put fresh pressure on Novo Nordisk's semaglutide franchise. Novo Nordisk's follow-up candidates have posted weaker results so far, leaving Ozempic and Wegovy to carry a franchise that now faces a rival acting on three hormone pathways at once.

For people living with type 2 diabetes, the practical question is less about which molecule wins a trial and more about access, cost and tolerability once a drug reaches the market. Weekly injections already require a routine patients can stick with, and stronger stomach side effects can be enough to make some stop treatment, as the discontinuation figures show. Pricing and insurance coverage for retatrutide remain unknown until Lilly files for approval and regulators weigh in.

About 650 participants from the trial are continuing into a 24-week extension study that will test longer-term safety and effectiveness, Lilly said. Full results from the retatrutide Ozempic trial have not been published yet, so doctors will be watching for the detailed safety data before judging how the drug fits alongside existing options, Reuters reported.